Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...
D. Boral Capital reissued their buy rating on shares of Quince Therapeutics (NASDAQ:QNCX – Free Report) in a report issued on Wednesday,Benzinga reports. D. Boral Capital currently has a $12.00 price ...
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the ...
company reiterates expectation of enrollment completion in second quarter of 2025 and topline results in fourth quarter of 2025 Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology ...
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that ...
Cyclo Therapeutics, Inc. ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and ...
Maxtech International, Inc. is releasing the 2025 edition of its market research report on military infrared detectors and systems markets (Vol. IRW-M). Global military infrared imaging systems ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results